Program

Due to postponing the meeting, the program is subject to change

Day 1

12:00 WELCOME

12:10 Renal histology in ANCA-associated vasculitis – Ingeborg Bajema
12:40 Pulmonary lesions in PR3-and MPO-ANCA vasculitis – Ulrich Specks
13:10 Beyond B-cell depletion in ANCA-associated vasculitis – new strategies ahead? – Benjamin Terrier

13:40 COFFEE BREAK

14:00 Drug-induced vasculitis – focus on anti-tumour agents – Alan Salama
14:30 IgG4-related disease: the true “chameleon” in medicine – John Stone

15:00 COFFEE BREAK

15:30 Diagnosis of monoclonal gammopathy of renal significance / multiple myeloma – Mariam (Priya) Alexander
16:00 Management of MGRS in the year 2020 – Nelson Leung
16:30 The complement system and multiple myeloma – David L. Murray
17:00 MM and AL-Amyloidosis – treatment in patients with compromised renal function. Choice and sequencing of drugs in 2020 – Evangelos Terpos

17:30 Come together & CONSENSUS PAPER Meeting

19:00 Conference DINNER

Day 2

09:00 Donors with history of malignancy – Hatem Amer
09:30 Post-tranplant lymphoproliferative disorder (PTLD): Evidence-based treatment – Heiner Zimmermann
10:00 Cancer risk in the CKD/transplant population – Hatem Amer

10:30 COFFEE

11:00 Pathomechanisms leading to hypercoagulability – Henri Versteeg
11:30 Cancer-associated thrombosis and management – Harry R. Büller
12:00 Thrombosis in the context of nephrotic syndrome – Jack Wetzels
12:30 Thrombotic microangiopathy: why do we need a multi-disciplinary management and how long shall we treat? – Ronald Go

13:00 LUNCH

14:00 Membranous nephropathy – Fernando Fervenza
14:30 Malignancy/tumour-associated nephrotic syndrome – Ladan Zand
15:00 Risk prediction model for AKI prior to initiation of cancer treatment – Shveta Motwani

15:30 COFFEE BREAK

16:00 Toxicity in the aera of CART cells – David Miklos
16:30 Nephrotoxicity of new cancer immunotherapies – Sandra Herrmann

17:00 Closing Remarks & END of the Meeting